AbbVie reported an increase in global net revenues to $15.121bn for Q4 2022. Credit: © AbbVie Inc. All rights reserved.

AbbVie has reported full-year 2022 net revenues of $58.054bn, representing a 3.3% rise on a reported basis and 5.1% on an operational basis.

The company reported an increase of 1.6% on a reported basis in global net revenues to $15.121bn for the fourth quarter (Q4) of 2022.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

For the full-year, worldwide net revenues from the Immunology portfolio stood at $28.924bn, increasing 14.4% on a reported basis.

Global net revenues of Humira for the full year stood at $21.237bn.

AbbVie also reported global Skyrizi and Rinvoq net revenues of $5.165bn and $2.522bn, respectively.

AbbVie chairman and CEO Richard Gonzalez said: “2022 was another highly productive year capping a decade of outstanding performance. Since our inception, we have built a diverse portfolio of growth products with significant leadership positions, developed a robust pipeline of innovative assets and created a culture of strong execution.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“Looking forward, we have a solid foundation which will allow us to absorb the US Humira loss of exclusivity, return to strong top-line growth in 2025 and drive top-tier financial performance over the long term.”

The company’s full-year worldwide net revenues from the Hematologic Oncology portfolio stood at $6.577bn, a 9% decline on a reported basis.

Imbruvica and Venclexta net revenues worldwide were $4.568bn and $2.009bn, respectively.

The Neuroscience portfolio reported full-year global net revenues of $6.528bn, which represented a 10.1% rise on a reported basis.

Additionally, AbbVie reported fourth-quarter diluted EPS of $1.38 on a GAAP Basis, a 38.9% decline.

Last month, AbbVie signed a global partnership and option agreement with Immunome to discover new antibody-target pairs to treat cancer.

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now